Table 3.
Summary of studies for 68Ga-PSMA PET/CT in primary lymph node staging for PCa patients based on per-node analysis.
| References | No of lymph nodes | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) |
|---|---|---|---|---|---|
| PER-NODE ANALYSIS | |||||
| Yaxley et al. (21) | 2,960 | 24 (18–32) | 99 (99–99) | 64 (51–75) | 96 (95–96) |
| Gupta et al. (22) | 243 | 67 (46–83) | 99 (96–100) | 86 (64–97) | 96 (92–98) |
| Zhang et al. (24) | 621 | 96 (87–100) | 100 (99–100) | 96 (87–100) | 100 (99–100) |
| van Leeuwen et al. (25) | 536 | 58 (37–77) | 100 (99–100) | 94 (70–100) | 98 (96–99) |
| Budaus et al. (26) | 608 | 64 (50–77) | 93 (90–95) | 46 (34–58) | 96 (94–98) |
| Herlemann et al. (27) | 71* | 84 (68–94) | 82 (65–93) | 84 (68–94) | 82 (65–93) |
| Maurer et al. (28) | 734 | 74 (65–81) | 99 (98–100) | 95 (88–98) | 95 (93–97) |
| POOLED ANALYSIS | |||||
| 5,773 | 70 (49–85) | 99 (96–100) | 85 (69–94) | 97 (93–98) | |
| Pooled PLR | 50.7 (15.9–162.1) | ||||
| Pooled NLR | 0.30 (0.16–0.56) | ||||
| Pooled DOR | 167 (40–695) | ||||
*
mixed participants; PSMA, prostate-specific membrane antigen; PET/CT, Positron Emission Tomography/Computerized Tomography; PCa, prostate cancer; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio.